Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Peter Singleton who wrote (4233)	3/5/1998 1:07:00 AM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 9719

Peter, This is a very interesting approach. I'll try to get the full article to see if I can understand it better. As for opinion, I like Ariad's and Vical's approaches. I think V1 has said one or two things about Targeted Genetics. For a slightly dated general summary see below. This summarizes an article that appeared in a BioVenture issue in late 1997. It has a list of companies involved in gene therapy classified by the kind of vectors/technology they have, as follows: A - viral in vivo B - viral ex vivo C - nonviral in vivo D - nonviral ex vivo E - targeted gene activation I have not checked for the accuracy of BioVenture's classifications and I may have made mistakes in the transcription. I am listing the ones I think are public or getting there; some, like Aviron or Genzyme Transgenics, have other areas of major focus. Company Vectors/technology Aastrom B, D Alexion A Apollon C Ariad ACE Avigen AE Aviron A Cell Genesys BE CellPro B CytoTherapeutics D GeneMedicine C GenVec AC GZTC AC Megabios C Progenitor C Ribozyme A Somatix AB Targeted Genetics ABC Transkaryotic DE Viagene CE Vical AE PB